Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The changing epidemiology of <i>Candida</i> species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios.

Expert review of anti-infective therapy·2025
Same author

Correction: Tegileridine: First Approval.

Drugs·2024
Same author

Ivonescimab: First Approval.

Drugs·2024
Same author

Tarlatamab: First Approval.

Drugs·2024
Same author

Tovorafenib: First Approval.

Drugs·2024
Same author

Zevorcabtagene Autoleucel: First Approval.

Molecular diagnosis & therapy·2024

Related Experiment Video

Updated: Jul 11, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Elranatamab: First Approval.

Sohita Dhillon1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|November 4, 2023
PubMed
Summary
This summary is machine-generated.

Elranatamab is a new bispecific antibody for treating relapsed or refractory multiple myeloma (RRMM). It targets B-cell maturation antigen (BCMA) and CD3 T cells, offering a novel therapeutic option for patients with advanced disease.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K

Related Experiment Videos

Last Updated: Jul 11, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
  • Relapsed or refractory multiple myeloma (RRMM) presents significant unmet needs, necessitating novel therapeutic strategies.
  • Existing treatments for RRMM include proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies.

Purpose of the Study:

  • To summarize the development milestones of elranatamab, a bispecific antibody for multiple myeloma.
  • To highlight the regulatory journey and first approval of elranatamab for RRMM.
  • To provide an overview of elranatamab's mechanism of action and clinical development.

Main Methods:

  • Elranatamab is a bispecific antibody engaging CD3 T cells with B-cell maturation antigen (BCMA)-expressing myeloma cells.
  • Mechanism involves T-cell activation and subsequent cytotoxicity against myeloma cells.
  • Development involved clinical trials to assess efficacy and safety in RRMM patients.

Main Results:

  • Elranatamab received US FDA accelerated approval in August 2023 for RRMM.
  • Approval was based on response rate and durability of response in patients with at least four prior lines of therapy.
  • Positive opinion received in the EU, with ongoing regulatory reviews in Japan and other countries.

Conclusions:

  • Elranatamab represents a significant advancement in the treatment of relapsed or refractory multiple myeloma.
  • The bispecific antibody mechanism offers a new therapeutic modality for heavily pretreated patients.
  • Continued clinical evaluation will be crucial for confirming its long-term clinical benefit.